CN104837865B - 衍生自髓样细胞触发受体-1(trem-1)trem-样转录物1(tlt-1)的抑制肽及其用途 - Google Patents

衍生自髓样细胞触发受体-1(trem-1)trem-样转录物1(tlt-1)的抑制肽及其用途 Download PDF

Info

Publication number
CN104837865B
CN104837865B CN201380058170.9A CN201380058170A CN104837865B CN 104837865 B CN104837865 B CN 104837865B CN 201380058170 A CN201380058170 A CN 201380058170A CN 104837865 B CN104837865 B CN 104837865B
Authority
CN
China
Prior art keywords
trem
tlt
peptide
seq
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380058170.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104837865A (zh
Inventor
塞巴斯蒂安·吉博
埃米尔·邦芬泽
阿菲德·艾特-乌尔费拉
马尔克·德里夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National Polytechnique de Lorraine
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National Polytechnique de Lorraine
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National Polytechnique de Lorraine, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National Polytechnique de Lorraine
Publication of CN104837865A publication Critical patent/CN104837865A/zh
Application granted granted Critical
Publication of CN104837865B publication Critical patent/CN104837865B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380058170.9A 2012-09-07 2013-09-09 衍生自髓样细胞触发受体-1(trem-1)trem-样转录物1(tlt-1)的抑制肽及其用途 Active CN104837865B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306079.0 2012-09-07
EP12306079 2012-09-07
PCT/EP2013/068628 WO2014037565A2 (en) 2012-09-07 2013-09-09 Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof

Publications (2)

Publication Number Publication Date
CN104837865A CN104837865A (zh) 2015-08-12
CN104837865B true CN104837865B (zh) 2019-09-24

Family

ID=46826397

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380058170.9A Active CN104837865B (zh) 2012-09-07 2013-09-09 衍生自髓样细胞触发受体-1(trem-1)trem-样转录物1(tlt-1)的抑制肽及其用途

Country Status (24)

Country Link
US (1) US9657081B2 (enExample)
EP (1) EP2892920B1 (enExample)
JP (1) JP6307080B2 (enExample)
KR (1) KR102181384B1 (enExample)
CN (1) CN104837865B (enExample)
AU (1) AU2013311606B2 (enExample)
CA (1) CA2884121C (enExample)
CY (1) CY1123014T1 (enExample)
DK (1) DK2892920T3 (enExample)
ES (1) ES2797625T3 (enExample)
HR (1) HRP20200875T8 (enExample)
HU (1) HUE051557T2 (enExample)
IL (1) IL237615B (enExample)
LT (1) LT2892920T (enExample)
MX (1) MX385794B (enExample)
NZ (1) NZ705899A (enExample)
PL (1) PL2892920T3 (enExample)
PT (1) PT2892920T (enExample)
RS (1) RS60421B1 (enExample)
RU (1) RU2672341C2 (enExample)
SI (1) SI2892920T1 (enExample)
SM (1) SMT202000309T1 (enExample)
WO (1) WO2014037565A2 (enExample)
ZA (1) ZA201501779B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
HK1254289A1 (zh) * 2015-06-12 2019-07-19 台湾基督长老教会马偕医疗财团法人马偕纪念医院 调控免疫反应的方法及抗体
WO2017152102A2 (en) 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
EP3836951A1 (en) 2018-08-13 2021-06-23 Signablok, Inc. Peptides and compositions for targeted treatment and imaging
WO2021105137A1 (en) 2019-11-25 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Trem-1 inhibitors for the treatment of vaso-occlusions and tissue injuries in patients suffering from sickle cell disease
EP4161551A1 (en) * 2020-06-05 2023-04-12 Inotrem Trem-1 inhibitor for use in the treatment of a subject suffering from a coronavirus infection
WO2021263167A2 (en) 2020-06-26 2021-12-30 Amgen Inc. Il-10 muteins and fusion proteins thereof
WO2022189659A1 (en) 2021-03-12 2022-09-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Trem-1 inhibitors for the treatment of marfan syndrome
US20240279332A1 (en) 2021-06-25 2024-08-22 Amgen Inc. Treatment of Cardiovascular Disease with TREM-1 Antigen Binding Proteins
WO2025196177A1 (en) 2024-03-21 2025-09-25 Institut National de la Santé et de la Recherche Médicale Use of soluble trem-1 as a biomarker for assessing the risk of cardiovascular disease in asymptomatic subjects

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056492A1 (en) * 2004-11-29 2006-06-01 Bioxell Spa Therapeutic peptides comprising sequences derived from cdr2 or cdr3 of trem-1 and uses thereof to inhibit sepsis
WO2011124685A1 (en) * 2010-04-08 2011-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
CA2156725A1 (en) 1993-02-22 1994-09-01 Warren S. Pear Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
HU222398B1 (hu) 1994-09-12 2003-06-28 Schering Aktiengesellschaft Eljárás pallidipin, egy módosított, kollagénindukált vérlemezke-aggregációt gátló vegyület előállítására
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO2002016416A2 (en) * 2000-08-22 2002-02-28 The Brigham And Women's Hospital, Inc. Diagnosis and treatment of cardiovascular conditions
US20040180409A1 (en) * 2003-03-16 2004-09-16 Mcvicar Daniel TLT-1, a novel platelet-associated receptor and uses therefor
US7553936B2 (en) * 2006-12-04 2009-06-30 The United States of America as represented by Secretary Department of Health and Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
CN101821621A (zh) 2007-07-23 2010-09-01 拜奥克塞尔有限公司 筛选、治疗和诊断
DE102009018620A1 (de) 2009-04-27 2010-10-28 Carefusion Germany 234 Gmbh Ansteuer- und Auswerteschaltung, Messgerät sowie Verfahren zum Messen der Konzentration eines Gases
JP5467313B2 (ja) * 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056492A1 (en) * 2004-11-29 2006-06-01 Bioxell Spa Therapeutic peptides comprising sequences derived from cdr2 or cdr3 of trem-1 and uses thereof to inhibit sepsis
WO2011124685A1 (en) * 2010-04-08 2011-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Effects of TREM-1 pathway modulation during mesenteric ischemia-reperfusion in rats.;Gibot s et al;《CRITICAL CARE MEDICINE》;20081231;第36卷(第2期);第505-507页,图1-3 *
Soluble trem-like transcript-1 regulates leukocyte activation and controls microbial sepsis;Derive m et al;《The Journal of Immunology》;20120601;第188卷(第11期);5585-5592 *
Trem-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humans;Washington A et al;《Journal of Clinical Investigation》;20090601;第119卷(第6期);1489-1501 *
Triggering receptor expressed on myeloid cells-1 as a new therapeutic target during inflammatory diseases;Derive M et al;《ImmuneRecognition and signaling》;20100731;第1卷(第3期);225-230 *

Also Published As

Publication number Publication date
MX385794B (es) 2025-03-18
EP2892920A2 (en) 2015-07-15
JP6307080B2 (ja) 2018-04-04
HK1212360A1 (en) 2016-06-10
RU2672341C2 (ru) 2018-11-14
LT2892920T (lt) 2020-07-10
SI2892920T1 (sl) 2020-08-31
IL237615A0 (en) 2015-04-30
SMT202000309T1 (it) 2020-07-08
CA2884121C (en) 2021-10-12
JP2015533791A (ja) 2015-11-26
HRP20200875T8 (hr) 2021-04-30
WO2014037565A3 (en) 2014-05-15
MX2015002994A (es) 2016-01-14
AU2013311606A1 (en) 2015-04-09
CA2884121A1 (en) 2014-03-13
EP2892920B1 (en) 2020-03-04
IL237615B (en) 2018-12-31
RU2015112625A (ru) 2016-10-27
CY1123014T1 (el) 2021-10-29
KR20150110460A (ko) 2015-10-02
WO2014037565A9 (en) 2015-06-11
WO2014037565A2 (en) 2014-03-13
KR102181384B1 (ko) 2020-11-20
US9657081B2 (en) 2017-05-23
RS60421B1 (sr) 2020-07-31
US20150232531A1 (en) 2015-08-20
HRP20200875T1 (hr) 2020-09-04
PT2892920T (pt) 2020-06-16
DK2892920T3 (da) 2020-06-08
NZ705899A (en) 2018-08-31
AU2013311606B2 (en) 2017-10-05
ZA201501779B (en) 2016-10-26
HUE051557T2 (hu) 2021-03-01
CN104837865A (zh) 2015-08-12
PL2892920T3 (pl) 2020-08-24
ES2797625T3 (es) 2020-12-03

Similar Documents

Publication Publication Date Title
CN104837865B (zh) 衍生自髓样细胞触发受体-1(trem-1)trem-样转录物1(tlt-1)的抑制肽及其用途
JP5918750B2 (ja) Trem様転写物1(tlt−1)から誘導された阻害性ペプチドおよびその使用
JPH05504053A (ja) ヒトC3b/C4bレセプター(CR1)
JP6092776B2 (ja) 可溶性補体受容体I型(sCR1)を用いる慢性腎症の処置
WO2019213686A1 (en) Therapeutic compositions and uses therefor
CN117083381A (zh) 用于靶向炎性细胞或活化细胞和治疗或改善炎性病症和疼痛的组合物和方法
ES2749076T3 (es) DNasa para uso en el tratamiento de crisis vaso-oclusivas
HK1212360B (en) Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof
JP2009539853A (ja) 抗プラスミン切断酵素の基質および阻害剤ならびにその使用
JP6339407B2 (ja) 脂質ラフトのクラスター形成抑制剤
WO2016083625A1 (en) Nucleic acid encoding triadin for the prevention and/or treatment of heart failure
AU2015202354A1 (en) Inhibiting peptides derived from TREM-like transcript 1 (TLT-1) and uses thereof
Abe et al. Complement in human disease
WO2015170778A1 (ja) ホスファチジルセリンの細胞表面への表出促進剤又は表出抑制剤、及び脂質ラフトのクラスター形成抑制剤

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant